$First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia$

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Abstract This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity of JNJ‐63709178, a CD123/CD3 dual‐targeting antibody, in patients with relapsed or refractory acute myeloid leukemia. Intraven...

Full description

Bibliographic Details
Main Authors:	Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, William Donnellan, Lucille Ferrante, Jenna D. Goldberg, Michael R. Grunwald, Christina Guttke, Xiang Li, Jose Antonio Perez‐Simon, Olga Salamero, Trevor Tucker, Xiaoying Xu, Jay Yang, Naveen Pemmaraju, Juan Manuel Alonso‐Dominguez
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.13467

Similar Items

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
by: Rupa Narayan, et al.
Published: (2024-03-01)

CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
by: Elodie Bôle-Richard, et al.
Published: (2022-05-01)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
by: Tianyu Cai, et al.
Published: (2022-04-01)

Diagnostic Challenges of CD4+/CD56+/CD123+ hematological neoplasms
by: Leandro S. Thiago, et al.
Published: (2013-08-01)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
by: Xiaohua Xue, et al.
Published: (2021-05-01)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
by: Siret Tahk, et al.
Published: (2021-09-01)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
by: Xiaohua Xue, et al.
Published: (2022-04-01)

Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia.
by: Chang Sook Hong, et al.
Published: (2014-01-01)

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
by: Michael Lai, et al.
Published: (2023-05-01)

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
by: Adhra Al-Mawali, et al.
Published: (2016-07-01)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
by: Ugo Testa, et al.
Published: (2019-09-01)

Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms
by: Elissandra Machado Arlindo, et al.

Increased expressions of CD123, CD63, CD203c, and Fc epsilon receptor I on blood leukocytes of allergic asthma
by: Hua Xie, et al.
Published: (2022-08-01)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
by: Simon Loff, et al.
Published: (2020-06-01)

P521: TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY
by: N. Pemmaraju, et al.
Published: (2022-06-01)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic
by: Salah Aref, et al.
Published: (2020-01-01)

Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy
by: Haidar H Al-Fatlawi, et al.
Published: (2016-01-01)

Scientific comment on: "Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms"
by: Maura Rosane Valerio Ikoma

P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML
by: N. G. Daver, et al.
Published: (2022-06-01)

Expression and significance of dendritic cell markers CD123, FXⅢA and CD1a in leprosy lesions
by: Wenjun ZHOU, et al.
Published: (2021-02-01)

Distribution of DC Subtypes: CD83+, DC-LAMP+, CD1a+, CD1c+, CD123+, and DC-SIGN+ in the Tumor Microenvironment of Endometrial Cancers—Correlation with Clinicopathologic Features
by: Grzegorz Dyduch, et al.
Published: (2023-01-01)

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies
by: Hanadi El Achi, et al.
Published: (2020-10-01)

Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models
by: Jianhua Gong, et al.
Published: (2020-01-01)

Fatal COVID-19 is Associated with Reduced HLA-DR, CD123 or CD11c Expression on Circulating Dendritic Cells
by: Hasan A, et al.
Published: (2022-10-01)

CD63 e CD123 expressão, autoanticorpos IgG e acurácia do teste do soro autólogo em pacientes com urticária crônica CD63 and CD123 expression, IgG autoantibody and accuracy of autologous serum test in patients with chronic urticaria
by: Zamir Calamita, et al.
Published: (2012-02-01)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
by: Gro Elise Rødland, et al.
Published: (2019-11-01)

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
by: J.G. Berdeja, et al.
Published: (2020-11-01)

CD11c- and CD123-positive dendritic cells in development of antitumour immunity in non-small cell lung cancer patients
by: Plamen Minkov, et al.
Published: (2019-09-01)

CD123 Is Consistently Expressed on <i>NPM1</i>-Mutated AML Cells
by: Vincenzo Maria Perriello, et al.
Published: (2021-01-01)

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
by: Margaux Poussard, et al.
Published: (2021-02-01)

Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia
by: Ibrahim Aldoss, et al.
Published: (2020-10-01)

Plasmacytoid Dendritic Cell marker (CD123) expression in scarring and non-scarring alopecia
by: Suganthi Krishnamurthy, et al.
Published: (2022-01-01)

Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment
by: Guo D, et al.
Published: (2020-01-01)

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
by: Nadia El Khawanky, et al.
Published: (2021-11-01)

P24 Differentiated monocytes express the pDC markers BDCA-2 and CD123
by: Edward M Vital, et al.
Published: (2024-03-01)

CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells
by: Wariya Nirachonkul, et al.
Published: (2021-11-01)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
by: Elvira Pelosi, et al.
Published: (2023-02-01)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
by: Mayumi Sugita, et al.
Published: (2022-04-01)

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
by: Janice M. Riberdy, et al.
Published: (2020-09-01)